HR 1816 · 111th Congress · Health

Ovarian Cancer Biomarker Research Act of 2009

Introduced 2009-03-31· Sponsored by Rep. Berman, Howard L. [D-CA-28]· House

Bill Progress

Introduced
2
Committee
3
House Vote
4
Senate
5
Enacted
Latest: Referred to the Subcommittee on Health.(2009-04-01)

Plain Language Summary

[AI summary unavailable — showing source text] Ovarian Cancer Biomarker Research Act of 2009 - Amends the Public Health Service Act to require the Director of the National Cancer Institute to enter into cooperative agreements with, or make grants to, public or nonprofit entities to establish and operate Ovarian Cancer Biomarker Centers of Excellence to conduct research on biomarkers for use in risk stratification for, and the early detection and screening of, ovarian cancer, focusing on translational research of such biomarkers. Permits federal funds to be used for research on: (1) the development and characterization of new biomarkers and the refinement of existing biomarkers; (2) the clinical and laboratory validation of such biomarkers; (3) the development and implementation of clinical and epidemiological research on the utilization of such biomarkers; (4) the development and implementation of repositories for new tissue, urine, serum, and other biological specimens; and (5) genetics, proteomics, and pathways of ovarian cancer as they relate to the discovery and development of biomarkers. Requires the Director to: (1) make available for research banked serum and tissue specimens from clinical research regarding ovarian canc…

Summarized by Claude AI · Non-partisan · For informational purposes only

Cosponsors (20)

16 Democrats4 Republicans